Table 5. Predicted risks categorized by clinical risk groups and the effect size differences between clinical risk groups.

	Predicted cardiovascular risks			Effect size differences between risk groups
	High‐risk n = 639	Medium‐risk n = 170	Low‐risk n = 28	High medium‐risk	High low‐risk	Medium low‐risk
(a) Predicted original cardiovascular risks
Framingham	39.46 ± 21.15	31.52 ± 19.29†	16.27 ± 12.10‡	0.38	1.10	0.72
PRC	9.73 ± 11.22	6.65 ± 8.49†	1.97 ± 1.73‡	0.29	0.73	0.44
UKPDS	26.79 ± 17.96	19.17 ± 14.47†	10.25 ± 9.37‡	0.43	0.94	0.51
JADE	15.64 ± 8.30	12.59 ± 6.62†	9.64 ± 5.77‡	0.38	0.74	0.37
(b) Converted annual total CHD risks
Framingham	2.67 ± 1.55	2.16 ± 1.40†	1.11 ± 0.89‡	0.33	1.01	0.68
PRC	0.28 ± 0.33	0.20 ± 0.25†	0.06 ± 0.05‡	0.25	0.69	0.44
UKPDS	3.35 ± 2.07	2.39 ± 1.65†	1.35 ± 1.04‡	0.47	0.99	0.51
JADE	3.13 ± 1.66	2.52 ± 1.32†	1.93 ± 1.15‡	0.38	0.75	0.37

Framingham, the risk function developed from the Framingham heart study; JADE, the risk function developed from the Joint Asia Diabetes Evaluation program; PRC, the risk function developed from USA–People's Republic of China Collaborative Study of Cardiovascular and Cardiopulmonary Epidemiology cohort; UKPDS, the risk engine developed from the United Kingdom Prospective Diabetes Study. †High‐risk group compared with medium risk group, P < 0.001; ‡Medium‐risk group compared with low‐risk group, P < 0.001.